FACTS
The U.S. Food and Drug Administration on Wednesday, Nov. 18, approved Sanofi’s venglustat, sold as Infilbray, for the neurological symptoms of type 3 Gaucher disease, Reuters reported. It is the first treatment approved for those symptoms. The once-daily tablet is approved for adults and children who weigh at least 15 kilograms, or about 33 pounds.
What type 3 Gaucher disease is
Type 3 Gaucher disease is a rare inherited disorder that causes fatty substances to build up in the body and the brain, according to Reuters. It affects the brain and nervous system as well as organs such as the spleen and liver.
Many patients already receive enzyme replacement therapy, given by IV infusion every two weeks, which treats symptoms outside the brain. Infilbray is the first drug approved to treat the neurological symptoms, Pharmacy Times reported.
The study behind the approval
The approval was based on a late-stage trial called LEAP2MONO, a randomized, double-blind phase 3 study of 43 patients age 12 and older, according to Pharmacy Times. All of them had been on enzyme replacement therapy for at least three years, with their disease outside the brain under control.
For 52 weeks, 21 patients took Infilbray by mouth once a day and 22 continued enzyme replacement therapy. Patients taking Infilbray showed a statistically significant improvement on a combined measure of muscle control, coordination and thinking skills, compared with those on enzyme replacement therapy.
Infilbray also met three of four key secondary goals, including spleen volume, liver volume and hemoglobin levels, performing comparably to enzyme replacement therapy on those measures, Pharmacy Times reported. An earlier, smaller phase 2 study enrolled 11 adults.
Side effects and warnings
The most commonly reported side effects were stomach and bowel problems and effects on mood, Reuters reported. In the trial, headache, nausea, diarrhea and an enlarged spleen were each reported in 14.3% of Infilbray patients, according to Pharmacy Times.
The drug’s label includes warnings about serious psychiatric risks, including suicidal thoughts and behavior. It also warns of possible clouding of the eye’s lens in younger patients, based on animal data, and of harm to a developing fetus if taken during pregnancy.
Review status
The FDA gave the drug orphan drug status, priority review and fast track designation, Pharmacy Times reported. Orphan status is granted to drugs for rare diseases.
This story discusses a medication’s reported risk of suicidal thoughts. If you or someone you know is struggling, call or text 988 to reach the Suicide and Crisis Lifeline in the United States.
More health coverage is on the Stay Current News Health page.







